CVT-313 is a selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK2, CDK7, and CDK9, which play critical roles in cell cycle regulation and transcription. Its primary application lies in cancer research, where it is used to study the effects of CDK inhibition on tumor cell proliferation and survival. By blocking CDK activity, CVT-313 induces cell cycle arrest and promotes apoptosis in various cancer cell lines, making it a valuable tool for investigating targeted anticancer therapies. It has shown potential in preclinical models for treating hematological malignancies and solid tumors, especially in combination with other chemotherapeutic agents. Additionally, CVT-313 is used to explore the role of transcriptional CDKs in viral replication and inflammatory responses, broadening its relevance in antiviral and immunomodulatory research.